sponsored
PatientsVille.com Logo

PatientsVille

FOSAMAX Medical Research Studies

Up-to-date List of FOSAMAX Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest FOSAMAX Medical Research Studies

Rank Status Study
1 Not yet recruiting The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults
Condition: Healthy Volunteers
Interventions: Drug: Alendronate;   Drug: Hepatitis B Vaccine;   Drug: Placebo
Outcome Measures: Safety/Adverse events;   Efficacy
2 Recruiting Testosterone and Alendronate in Hypogonadal Men
Conditions: Hypogonadism;   Osteopenia;   Osteoporosis
Interventions: Drug: Testosterone;   Drug: Alendronate;   Drug: Placebo Alendronate;   Drug: Placebo Testosterone
Outcome Measure: Spine Bone Mineral Density by DXA
3 Unknown  Alendronate for Vascular Calcification in Peritoneal Dialysis Patients?
Condition: Peritoneal Dialysis
Intervention: Drug: alendronate (Fosamax)
Outcome Measures: 1.Changes of calcification score of coronary arteries and aorta;   2.Changes of bone density;   changes of parathyroid hormone;   changes of serum calcium and phosphate level;   changes of C reactive protein;   changes of lipid profile;   adverse reactions
4 Unknown  Fosamax for Childhood Cancer Survivors
Condition: Osteoporosis
Interventions: Drug: Alendronate;   Drug: Placebo
Outcome Measures: The percent change in bone mineral density (BMD) at lumbar spine at 36-weeks in subjects who receive active and control treatments;   Changes in BMD at femoral neck;   Changes in biochemical markers of bone turnover;   Occurrence of clinical bone-related symptoms at 12-weeks and end of this study
5 Not yet recruiting RA Denosumab on Bone Microstructure Study
Condition: Rheumatoid Arthritis
Interventions: Drug: Denosumab;   Drug: Alendronate
Outcome Measures: Changes from baseline in bone volumetric density at distal radius at 6th month;   Changes from baseline in trabecular bone microarchitecture at distal radius at 6th month;   Changes from baseline in bone volumetric density at the 2nd metacarpal bone at 6th month;   Changes from baseline in trabecular bone microarchitecture at 2nd metacarpal bone at 6th month;   Changes from baseline in areal bone density at total hip at 6th month;   Changes from baseline in areal bone density at lumbar spine at 6th month;   Changes in areal bone density at distal radius at 6th month;   Changes from baseline in bone volumetric density at distal radius at 3rd month;   Changes from baseline in trabecular bone microarchitecture at distal radius at 3rd month;   Changes from baseline in bone volumetric density at the 2nd metacarpal bone at 3rd month;   Changes from baseline in trabecular bone microarchitecture at 2nd metacarpal bone at 3rd month;   Changes from baseline in areal bone density at total hip at 3rd month;   Changes from baseline in areal bone density at lumbar spine at 3rd month;   Changes in areal bone density at distal radius at 3rd month
6 Recruiting Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis
Condition: Postmenopausal Women With Osteoporosis
Interventions: Drug: Romosozumab;   Drug: Alendronate
Outcome Measures: Incidence of clinical fracture;   Incidence of new vertebral fracture;   Incidence of fracture;   Percent changes in DXA Bone Mineral Density from baseline to 12 months;   Percent changes in DXA Bone Mineral Density from baseline to 24 months;   Percent changes in DXA Bone Mineral Density from baseline to 36 months
7 Not yet recruiting Bone Antiresorptive Therapy With Antiretroviral Initiation (BATARI) Pilot Trial
Condition: HIV
Intervention: Drug: alendronate/vitamin D
Outcome Measures: Percentage changes in BMD at a) the lumbar spine and b) proximal femur;   Feasibility;   Acceptability;   Safety/Tolerability;   Adherence;   Bone Biomarkers
8 Not yet recruiting Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis.
Condition: Calcific Aortic Stenosis
Interventions: Drug: Denosumab;   Drug: Alendronic Acid;   Drug: Denosumab Placebo;   Drug: Alendronic Acid Placebo
Outcome Measures: Change in aortic valve calcium score;   Change in aortic valve 18F-NaF uptake;   Change in aortic-jet velocity;   Change in thoracic aortic and coronary artery calcium score;   Change in thoracic spine bone mineral density;   Change in quality of life determined by Short Form 36 Questionnaire
9 Recruiting Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy
Condition: Osteoporosis
Interventions: Drug: Alendronate;   Drug: Placebo
Outcome Measures: Incidence of new osteoporotic fractures;   Equivalence of deaths with and without continued bisphosphonate therapy;   Incidence of the combination of fractures and deaths
10 Recruiting Bone Healing After Dental Extraction in Postmenopausal Osteoporotic Women Treated With Alendronate Per os Weekly
Condition: Alveolar Bone Healing After Dental Extraction
Intervention: Procedure: Dental extraction
Outcome Measures: Alveolar socket filled by new bone;   Mucosal injury
11 Unknown  The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.
Condition: Osteoporosis
Intervention: Drug: Alendronate
Outcome Measure:
12 Unknown  Osteoporosis and Dental Implant
Condition: Osteoporosis
Interventions: Drug: alendronate once weekly 70mg;   Drug: placebo
Outcome Measure: Dental CT
13 Unknown  Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis
Conditions: Osteoporosis;   Cystic Fibrosis
Interventions: Drug: alendronate sodium;   Drug: calcium carbonate;   Drug: cholecalciferol
Outcome Measure:
14 Unknown  Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease
Conditions: Gaucher's Disease;   Osteopenia
Interventions: Drug: alendronate sodium;   Drug: calcium carbonate;   Drug: cholecalciferol
Outcome Measure:
15 Unknown  Pharmacokinetics of Maxmarvil® in Healthy Postmenopausal Women
Condition: Osteoporosis
Intervention: Drug: Maxmarvil®
Outcome Measure: analysis of Alendronate concentrate
16 Recruiting Stem Cell Recruitment in Osteoporosis Therapy
Condition: Low Bone Density
Interventions: Drug: Teriparatide;   Drug: Alendronate;   Dietary Supplement: calcium and vitamin D
Outcome Measures: Number of Stro-1+ MSCs at bone resorption sites in bone biopsies of subjects treated with PTH or ALN.;   Number of p-Smad 2/3+ cells/mm2 at active resorption sites on bone biopsy specimens of subjects treated with PTH or ALN.;   The percent increase in Stro-1+/CD146+ cells in the blood before and after treatment with PTH or ALN.;   Number of human Stro-1+ MSCs at bone resorption sites in bone of Rag2-/- mice reconstituted with human bone marrow derived from subjects treated with PTH or ALN.
17 Recruiting Twenty Four Month Extension Study of BA058-05-003
Condition: Postmenopausal Osteoporosis
Intervention: Drug: Alendronate
Outcome Measures: Safety;   Vertebral Fracture Incidence;   Non-vertebral Fracture Incidence
18 Recruiting Bisphosphonate Biomarker Study
Conditions: Osteoporosis, With or Without Treatment;   Bisphosphonate Treatment;   Atypical Femur Fracture;   Bisphosphonate Related Osteonecrosis of the Jaws (BRONJ);   Healthy Volunteers
Intervention:
Outcome Measures: Absorption, Distribution, Metabolism, Excretion (ADME) Profiling of DNA from all sample types vs. normative data for the ADME panel and across study groups;   Differential expression of miRNA biomarkers across participant groups within the study
19 Recruiting Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study
Condition: Osteoporosis
Intervention: Drug: Alendronate
Outcome Measures: Clinical site recruitment rate;   Participant recruitment rate;   Contracting and procedures;   Administrative procedures;   Osteonecrosis of the jaw;   Atypical femoral fracture;   Clinical fracture rate
20 Recruiting Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
Condition: Postmenopausal Osteoporosis
Intervention: Drug: Teriparatide 40-mcg subcutaneous injection
Outcome Measure: Bone turnover marker (blood sample)

These studies may lead to new treatments and are adding insight into FOSAMAX etiology and treatment.

A major focus of FOSAMAX research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss FOSAMAX